{"id":142343,"date":"2023-02-21T05:38:08","date_gmt":"2023-02-21T10:38:08","guid":{"rendered":"https:\/\/44.250.171.167\/?p=142343"},"modified":"2023-02-21T05:38:09","modified_gmt":"2023-02-21T10:38:09","slug":"earningsaarti-drugs-ltd-nseaartidrugs-q3fy23-results-out-total-income-rise-4-yoy","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/earningsaarti-drugs-ltd-nseaartidrugs-q3fy23-results-out-total-income-rise-4-yoy\/","title":{"rendered":"Earnings|Aarti Drugs Ltd (NSE:AARTIDRUGS): Q3FY23 Results Out; Total Income rise 4% YoY"},"content":{"rendered":"\n

Aarti Drugs Ltd (NSE:AARTIDRUGS)<\/a> is a leading Indian pharmaceutical company that specializes in the manufacture and export of bulk drugs. The company has a diverse product portfolio that includes APIs, intermediates, specialty chemicals, and nutraceuticals. Aarti Drugs is headquartered in Mumbai and has manufacturing facilities located in Tarapur, Vapi, and Dombivali. The company’s products are sold in over 60 countries, including the US, Europe, and Asia.<\/p>\n\n\n\n

Aarti Drugs Ltd announced its Q3FY23 results, reporting a consolidated revenue of Rs 1,975.0 crore, a growth of 10% YoY from Rs 1,802.7 crore. The company’s EBITDA for the quarter was reported at Rs 213.4 crore, compared to Rs 251.8 crore YoY, which was driven by a decline in EBITDA margin (%) from 14% to 10.8%. The company’s PAT for the quarter stood at Rs 110.2 crore, compared to Rs 149.7 crore YoY, resulting in a decline in PAT margin (%) from 8.3% to 5.6%.<\/p>\n\n\n\n

For the 9MFY23 period, Aarti Drugs Ltd reported a revenue of Rs 665.0 crore, a growth of 4% YoY from Rs 641.5 crore. The company’s EBITDA was reported at Rs 71.7 crore, compared to Rs 96.7 crore YoY, which was driven by a decline in EBITDA margin (%) from 15.1% to 10.8%. The company’s PAT for the period stood at Rs 36.7 crore, compared to Rs 58.3 crore YoY, resulting in a decline in PAT margin (%) from 9.1% to 5.5%.<\/p>\n\n\n\n

The company’s standalone business reported a revenue of Rs 626.5 crore, a growth of 5% YoY from Rs 594.8 crore, which contributed ~92% to the consolidated revenue for the quarter. The company’s revenue was majorly driven by the domestic market, contributing 61% of the revenues, while the rest came from the export market. The company’s domestic revenue grew approximately by 8%, while exports grew by around 2% YoY for Q3FY23.<\/p>\n\n\n\n

Commenting on the results, Mr. Adhish Patil, Chief Financial Officer of Aarti Drugs Ltd, mentioned that the company’s overall API revenue for the quarter grew by 9% YoY. However, due to a correction in raw material prices, the company made some price adjustments to defend its market share, which resulted in inventory loss of approx. Rs 6 crores as a prudent practice. The gross margins were impacted by almost ~100 bps during the quarter due to API price correction. The company increased the inventory levels of imported KSMs and other raw materials due to a sudden spike of Covid-19 cases and holidays related to the Chinese new year. The finance cost also increased due to higher working capital requirements and rising interest rates.<\/p>\n","protected":false},"excerpt":{"rendered":"

Aarti Drugs Ltd (NSE:AARTIDRUGS) is a leading Indian pharmaceutical company that specializes in the manufacture and export of bulk drugs. The company has a diverse product portfolio that includes APIs, intermediates, specialty chemicals, and nutraceuticals. Aarti Drugs is headquartered in Mumbai and has manufacturing facilities located in Tarapur, Vapi, and Dombivali. The company’s products are […]<\/p>\n","protected":false},"author":1932,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[392,5747],"tags":[1115],"class_list":["post-142343","post","type-post","status-publish","format-standard","hentry","category-earnings","category-healthcare-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":144684,"url":"https:\/\/alphastreet.com\/india\/earnings-aarti-drugs-ltd-nse-aartidrugs-q4fy23-results-out-total-income-rise-8-5-yoy\/","url_meta":{"origin":142343,"position":0},"title":"Earnings | Aarti Drugs Ltd. (NSE: AARTIDRUGS): Q4FY23 Results Out; Total Income rise 8.5% YoY","author":"Divyansh_Kasana","date":"May 1, 2023","format":false,"excerpt":"Aarti Drugs Ltd. is an Indian pharmaceutical company that specializes in the development, manufacturing, and marketing of active pharmaceutical ingredients (APIs), intermediates, and formulations. The company has a global presence and exports its products to more than 60 countries. Aarti Drugs has a strong focus on research and development and\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-7.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-7.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-7.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-7.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-7.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-7.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170447,"url":"https:\/\/alphastreet.com\/india\/aarti-drugs-q1-fy26-earnings-results\/","url_meta":{"origin":142343,"position":1},"title":"Aarti Drugs Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 21, 2025","format":false,"excerpt":"Aarti Drugs Ltd, established in 1984 and part of the $1000 million Aarti Group of Industries, is engaged in manufacturing and selling Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals, as well as pharmaceutical formulations. Presenting below are its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b9591 crore,\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"AARTIDRUGS Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":140880,"url":"https:\/\/alphastreet.com\/india\/aarti-industries-ltd-nse-aartiind-q3-fy23-results-out-total-income-fell-15-yoy\/","url_meta":{"origin":142343,"position":2},"title":"AARTI INDUSTRIES LTD. (NSE: AARTIIND): Q3 FY23 Results Out; Total Income fell 15% YoY","author":"Divyansh_Kasana","date":"February 10, 2023","format":false,"excerpt":"Aarti Industries ltd. (NSE:AARTIIND), a specialty chemical firm, recently announced its Q3FY23 financial results. The company reported a revenue of Rs 1,854 crore, an increase of 12% YoY. The EBITDA for the quarter was Rs 289 crore, which was a 26% increase YoY. The PAT for the quarter was Rs\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":142550,"url":"https:\/\/alphastreet.com\/india\/earnings-aurobindo-pharma-ltd-nseauropharma-q3fy23-results-out-total-income-rise-7-yoy\/","url_meta":{"origin":142343,"position":3},"title":"Earnings | Aurobindo Pharma Ltd. (NSE:AUROPHARMA): Q3FY23 Results Out; Total Income rise 7% YoY","author":"Divyansh_Kasana","date":"February 22, 2023","format":false,"excerpt":"Aurobindo Pharma Ltd. (NSE:AUROPHARMA) is a global pharmaceutical company headquartered in India. The company produces and sells a wide range of generic pharmaceutical products and active pharmaceutical ingredients (APIs) in over 150 countries. Aurobindo Pharma's portfolio includes antibiotics, anti-retrovirals, anti-inflammatory drugs, cardiovascular drugs, and more. The company operates manufacturing facilities\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":172552,"url":"https:\/\/alphastreet.com\/india\/aarti-drugs-q2-fy26-earnings-results\/","url_meta":{"origin":142343,"position":4},"title":"Aarti Drugs Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"November 20, 2025","format":false,"excerpt":"Aarti Drugs Ltd, part of the Aarti Group of Industries, engaged in manufacturing APIs, pharma intermediates, specialty chemicals, and formulations, reported strong results for Q2FY26. Financial Highlights: Revenues increased 9.2% year-on-year to \u20b9653 crore from \u20b9598 crore. Total expenses rose 7.04% to \u20b9593 crore from \u20b9554 crore. Consolidated net profit\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/DRUGS.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/DRUGS.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/DRUGS.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/DRUGS.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/DRUGS.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/DRUGS.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":141647,"url":"https:\/\/alphastreet.com\/india\/biocon-ltd-nse-biocon-ltd-q3-fy23-results-out-total-income-rise-35-yoy\/","url_meta":{"origin":142343,"position":5},"title":"Biocon ltd.(NSE: BIOCON) Ltd. : Q3 FY23 Results Out; Total Income rise 35% YoY","author":"Divyansh_Kasana","date":"February 14, 2023","format":false,"excerpt":"Biocon Limited (NSE:BIOCON) is an Indian multinational biopharmaceutical company based in Bangalore, India. The company was founded in 1978 by Kiran Mazumdar-Shaw and is now one of the largest biopharmaceutical companies in India. Biocon is primarily engaged in the production of biosimilars, generic biologics, and research-based pharmaceuticals. It also has\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/5ae0e933-d8c2-4fc6-912a-65a97b6504cf.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/5ae0e933-d8c2-4fc6-912a-65a97b6504cf.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/5ae0e933-d8c2-4fc6-912a-65a97b6504cf.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/5ae0e933-d8c2-4fc6-912a-65a97b6504cf.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/5ae0e933-d8c2-4fc6-912a-65a97b6504cf.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/5ae0e933-d8c2-4fc6-912a-65a97b6504cf.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/142343","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=142343"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/142343\/revisions"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=142343"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=142343"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=142343"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}